Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Friday morning. The firm issued a sell rating on the stock.

Oragenics Trading Down 7.6 %

NYSE OGEN opened at $0.22 on Friday. The business has a fifty day simple moving average of $0.28 and a 200 day simple moving average of $0.33. Oragenics has a 12 month low of $0.21 and a 12 month high of $3.43. The firm has a market capitalization of $4.64 million, a P/E ratio of -0.03 and a beta of 0.85.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.